NCT05135091

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2022-06-16Est. Completion: 2029-02

Enrollment target: 88 participants

Locations

University of Alabama, Birmingham, Alabama, United States
Mayo Clinic Arizona Epilepsy Center, Phoenix, Arizona, United States
Banner-University of Arizona Medical Center Tucson Comprehensive Epilepsy Program, Tucson, Arizona, United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
University of Southern California Keck Hospital, Los Angeles, California, United States
University of California Los Angeles, Los Angeles, California, United States
UC Irvine Medical Center, Orange, California, United States
Stanford University, Palo Alto, California, United States
University of California Davis, Sacramento, California, United States
University of California San Diego, San Diego, California, United States
University of California San Francisco, San Francisco, California, United States
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
George Washington University, Washington D.C., District of Columbia, United States
University of Miami, Miami, Florida, United States

Mesial Temporal Lobe Epilepsy

The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of…

Birmingham, United StatesEst. completion Nov 30, 2026

Patients With Drug-resistant Focal EpilepsySEEG as Part of Presurgical Evaluation

Interactions between epilepsy and sleep are numerous and bidirectional. Sleep can facilitate epileptic activity and seiz…

Durham, United StatesEst. completion Jun 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.